4 291

Cited 6 times in

Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without caridiovascular event

 Ji Hye Huh  ;  Hannah Seok  ;  Byung-Wan Lee  ;  Eun Seok Kang  ;  Hyun Chul Lee  ;  Bong Soo Cha 
 ENDOCRINE, Vol.47(1) : 138-145, 2014 
Journal Title
Issue Date
Aged ; Cardiovascular Diseases/prevention & control* ; Carotid Arteries/diagnostic imaging ; Carotid Arteries/drug effects* ; Carotid Intima-Media Thickness* ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnostic imaging ; Diabetes Mellitus, Type 2/drug therapy* ; Diabetes Mellitus, Type 2/epidemiology ; Disease Progression ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/pharmacology* ; Platelet Aggregation Inhibitors/therapeutic use ; Retrospective Studies ; Tetrazoles/pharmacology* ; Tetrazoles/therapeutic use ; Treatment Outcome
Intima-media thickness (IMT) ; Type 2 diabetes mellitus ; Cilostazol ; Lipid profile
We investigated the efficacy of cilostazol treatment for 2 years on the attenuation of carotid intima-media thickness (IMT) progression in type 2 diabetic patients without cardiovascular disease history, as compared with other antiplatelet agents. We recruited a total of 230 type 2 diabetic patients who had undergone IMT measurement twice within 1.5–2.5 years (mean 2.06 ± 0.32 years) interval. Among these participants, we classified them into three groups according to antiplatelet agent administration at baseline: Group I (n = 66), antiplatelet naïve; Group II (n = 75), other antiplatelet agent administration; and Group III (n = 50), cilostazol administration. We then analyzed the changes in clinical characteristics from baseline to 2 years. The changes in annual mean IMT at 2 years were 0.019 ± 0.045 mm/year, −0.001 ± 0.058 mm/year, and −0.019 ± 0.043 mm/year for Group I, II, and III, respectively (P < 0.001). Mean change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride compared with baseline decreased the most in Group III even after adjustment for statin use. We also observed that the odds ratio of carotid IMT progression at 2 years was the lowest in patients who were treated with cilostazol even after adjustment for change of metabolic parameters. When we categorized patients according to baseline carotid IMT tertile, the efficacy of cilostazol against carotid IMT progression was significant only when baseline IMT was over 0.662 mm (mean 0.801). Two-year treatment with cilostazol strongly inhibited carotid IMT progression compared to other antiplatelet agents in type 2 diabetic patients. This beneficial effect of cilostazol was significant when baseline IMT was thicker than 0.662 mm (mean 0.801 mm).
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Lee, Byung Wan(이병완) ORCID logo https://orcid.org/0000-0002-9899-4992
Lee, Hyun Chul(이현철)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.